AI pricing strategy in APAC and Middle East biotech markets: beyond the EU5 reference price Most biotech companies price their products in APAC and the Middle East by anchoring to the EU5 reference price and adjusting downward. This approach has structural problems that compound across products and markets over a commercial lifecycle. It ignores local […]
AI vendor due diligence for biotech executives: what to ask before you buy Most biotech executives are receiving at least one AI vendor pitch every week. The tools range from genuinely useful to actively risky, and the marketing language is nearly identical across the spectrum. Very few executives have a structured framework for deciding which
AI vendor due diligence for biotech executives: what to ask before you buy Read More »
AI clinical trial site selection: how to find the right sites before your competitor does 30% of clinical trial sites enrol zero patients. That statistic has not changed materially in two decades despite decades of site selection process improvement. The fundamental problem is that traditional site selection is relationship-driven and backward-looking. AI is changing both
AI in biotech deal structuring: how to model partnerships before you sign them In 2025, AI and machine learning drug discovery licensing deals totalled $43.4 billion across 114 transactions. That is a significant acceleration from prior years, and the deals are getting more structurally complex. Platform licensing deals, foundation model partnerships, and multi-asset collaboration agreements
AI in biotech deal structuring: how to model partnerships before you sign them Read More »
AI in aggregate safety reporting: how to cut PBRER production time without cutting corners A Periodic Benefit-Risk Evaluation Report for a product with a large safety database can take a team of five people six to eight weeks to produce. That cycle repeats every year for every authorised product in your portfolio. For a biotech
AI post-approval regulatory monitoring: how to stay ahead of lifecycle obligations Approval is not the finish line. It is where the regulatory workload begins. Labelling variations. REMS updates. Post-marketing commitments. PSURs. Regulatory intelligence monitoring across every authorised market. For a biotech with products in 30 or 40 countries, managing the post-approval regulatory landscape is a
AI post-approval regulatory monitoring: how to stay ahead of lifecycle obligations Read More »
AI payer intelligence in biotech: how to stop guessing what reimbursement bodies want Most biotech market access strategies are built on past HTA decisions and consultant intuition. That is a fragile foundation when payer bodies are changing their evidence requirements faster than most teams can track. In 2025, the pace of regulatory and reimbursement guidance
AI payer intelligence in biotech: how to stop guessing what reimbursement bodies want Read More »
AI distributor performance monitoring in emerging markets: beyond the quarterly review Most biotech companies review distributor performance once a quarter. In markets like the Middle East, Southeast Asia, or Eastern Europe, a lot can go wrong in 90 days. Inventory builds up in the wrong geography. A distributor drops pricing below the contractual floor to
AI distributor performance monitoring in emerging markets: beyond the quarterly review Read More »
AI in CDMO selection and management: how to pick the right partner and hold them accountable More than 50% of global biotech drug manufacturing is handled by contract development and manufacturing organisations. For most biotech companies, the CDMO is the single most critical external dependency in their supply chain. A CDMO failure does not just
AI in biotech talent acquisition: how to hire faster without lowering the bar Anthropic paid over $400 million for a team of fewer than 10 computational biologists this week. That works out to approximately $40 million per person. That is the talent market biotech companies are competing in when they try to hire AI-specialist roles
AI in biotech talent acquisition: how to hire faster without lowering the bar Read More »
